H.C. Wainwright lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $11 from $12 and keeps a Buy rating on the shares following the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook
- Y-mAbs Therapeutics price target lowered to $20 from $21 at Oppenheimer
- Positive Outlook for Y-Mabs Therapeutics Amid Strategic Developments and NCCN Inclusion
- Y-mAbs Therapeutics Reports Q1 2025 Financial Results
- Cautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges